<DOC>
	<DOCNO>NCT00616941</DOCNO>
	<brief_summary>This open label , Phase I study vaccination NY-ESO-1 OLP4 without immunoadjuvant Montanide Poly-ICLC patient epithelial ovarian , fallopian tube , primary peritoneal cancer second third clinical remission . The primary secondary endpoint study determine safety immunogenicity NY-ESO-1 OLP4 vaccination without immunoadjuvants Montanide Poly-ICLC .</brief_summary>
	<brief_title>A Phase I Study NY-ESO-1 Overlapping Peptides ( OLP4 ) Immunoadjuvants Montanide Poly-ICLC Vaccination Epithelial Ovarian Cancer ( EOC ) , Fallopian Tube , Primary Peritoneal Cancer Patients Second Third Remission</brief_title>
	<detailed_description>Cohort I ( n=3 ) receive NY-ESO-1 OLP4 subcutaneous injection every 3 week ( week 1 , 4 , 7 , 10 , 13 ) total 5 vaccination . At week 16 patient return final toxicity immunologic assessment . If 0/3 DLT 's see Cohort I , arm consider safe accrual arm stop . If 1/3 patient experience DLT ( define section 11 ) , 3 patient accrue . If 1/6 experience DLT arm consider safe . If &gt; 1/6 patient arm experience DLT arm consider safe , accrual study stop . If arm consider safe proceed Cohort II . Cohort II ( n=3 + 6 ) receive NY-ESO-1 OLP combination Montanide immune adjuvant subcutaneous injection , every 3 week ( week 1 , 4 , 7 , 10 , 13 ) total 5 vaccination . At week 16 patient return final toxicity immunologic assessment . If 0/3 initial patient experience DLT add 6 patient arm dose schedule describe , total 9 patient . If 1/3 patient DLT , accrue 3 patient dose schedule . If 1/6 DLT arm consider safe , 3 patient test . Cohort III begin accrual 6 patient cohort II receive 5 vaccination one DLT observe ( criterion already meet study ) . Cohort III ( n=3 + 6 ) receive NY-ESO-1 OLP mixed Poly-ICLC immunoadjuvant emulsify Montanide subcutaneous injection , every 3 week ( week 1 , 4 , 7 , 10 , 13 ) total 5 vaccination . At week 16 , patient return final toxicity immunologic assessment . If 0/3 initial patient Cohort III experience DLT , 6 patient add total 9 evaluable patient . If 1/3 initial patient DLT , 3 patient accrue cohort III . If 1/6 patient DLT , arm consider safe , 3 patient accrue . Patient 's vital sign monitor one hour follow vaccination , The three cohort accrue sequentially . Cohort I accrue directly . Cohort II begin accrual least one patient cohort I receive 5 vaccination . Cohort III begin accrual 6 patient cohort II receive 5 vaccination one DLT observe ( criterion already meet study ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>Patients must histologically document epithelial carcinoma arise ovary , fallopian tube , peritoneum , stage IIIV diagnosis , receive initial cytoreductive surgery chemotherapy least one platinum base chemotherapy regimen . Patients must second third complete clinical remission . Stable complete clinical remission define ) Stable CA125 &lt; 35U/ml , ( define CA125 double post chemotherapy nadir , b ) unremarkable physical examination , c ) definite evidence disease compute tomography ( CT ) abdomen pelvis . Lymph node and/or soft tissue abnormality ≤ 1.0 cm often present pelvis , may consider definite evidence disease . Expected survival least 4 month . Karnofsky performance scale ≥70 % . Laboratory value within follow limit : Hemoglobin &gt; 10.0 g/dL Neutrophil count &gt; 1.5 x l09/L Platelet count &gt; 80 x l09/L Serum creatinine &lt; 2.0 mg/dL Serum bilirubin &lt; 2.5 x upper limit institutional normal AST/ALT &lt; 2.5 x upper limit institutional normal Age ≥ 18 year . Patient &gt; 4 week completion prior cytotoxic chemotherapy . Able willing give valid write informed consent Clinically significant heart disease ( NYHA Class III IV ) . Patients serious intercurrent illness , e.g. , serious infection require prolonged parenteral antibiotic bleed disorder require hospitalization . Patients positive stool guaiac exclude hemorrhoid . Patients know autoimmune disease ( ie rheumatoid arthritis , ulcerative colitis etc ) ; immune deficiency ( HIV , hypogammaglobulinemia ) ; know active infection Hepatitis B Hepatitis C ; receive immunosuppressive drug systemic corticosteroid cyclosporin , etc ) . Other malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ . History previous severe allergic reaction vaccine unknown allergen . Mental impairment may compromise ability give informed consent comply requirement study . Lack availability immunological clinical followup assessment . Participation clinical trial involve another investigational agent within 4 week prior first dose study agent . Pregnancy breastfeed . Women childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>NY-ESO-1 OLP4</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cancer Vaccine</keyword>
</DOC>